GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Shares Outstanding (EOP)

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Shares Outstanding (EOP) : 167 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Dr Reddy's Laboratories's shares outstanding for the quarter that ended in Dec. 2023 was 167 Mil.

Dr Reddy's Laboratories's quarterly shares outstanding increased from Sep. 2023 (166 Mil) to Dec. 2023 (167 Mil). It means Dr Reddy's Laboratories issued new shares from Sep. 2023 to Dec. 2023 .

Dr Reddy's Laboratories's annual shares outstanding increased from Mar. 2022 (166 Mil) to Mar. 2023 (166 Mil). It means Dr Reddy's Laboratories issued new shares from Mar. 2022 to Mar. 2023 .


Dr Reddy's Laboratories Shares Outstanding (EOP) Historical Data

The historical data trend for Dr Reddy's Laboratories's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Shares Outstanding (EOP) Chart

Dr Reddy's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.85 165.78 165.73 165.96 166.16

Dr Reddy's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.10 166.16 166.21 166.49 166.51

Competitive Comparison of Dr Reddy's Laboratories's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Shares Outstanding (EOP) falls into.



Dr Reddy's Laboratories Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Dr Reddy's Laboratories  (NYSE:RDY) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Dr Reddy's Laboratories Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Headlines

From GuruFocus

Dr. Reddy's Q1 FY24 Financial Results

By Business Wire 07-26-2023